• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

    7/26/23 8:00:00 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ICPT alert in real time by email

    MORRISTOWN, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, will announce its second quarter 2023 financial results on Wednesday, August 2, 2023. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.

    Participants can access the conference call live via webcast which will be available on the investor page of the company's website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event's start. A replay of the call will be available on Intercept's website following the completion of the call.

    About Intercept     

    Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.

    Contact     

    For more information about Intercept, please contact:

    Investor inquiries: [email protected]

    Media inquiries: [email protected]



    Primary Logo

    Get the next $ICPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICPT

    DatePrice TargetRatingAnalyst
    7/13/2023$8.00 → $19.00Sell → Buy
    H.C. Wainwright
    6/29/2023$12.00 → $18.00Hold → Buy
    Canaccord Genuity
    5/23/2023Buy → Hold
    Needham
    5/22/2023$8.00Neutral → Sell
    H.C. Wainwright
    5/17/2023Outperform → Mkt Perform
    Raymond James
    3/8/2022$31.00 → $29.00Hold
    Canaccord Genuity
    3/3/2022$22.00 → $16.00Sector Perform
    RBC Capital
    3/3/2022$30.00 → $25.00Buy
    Needham
    More analyst ratings

    $ICPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      2/25/22 4:36:46 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

      Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

      5/27/21 5:23:24 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ICPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference

      MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abstracts on primary biliary cholangitis (PBC) will be presented at Digestive Disease Week® (DDW) 2024. The conference will be held from May 18-21 in Washington, D.C. "We are pleased to participate in this year's DDW and share our latest findings, including new data from our Phase 2 trial evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with PBC," said Sangeeta Sawh

      5/9/24 8:00:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC

      sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBCPrecedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registriesFDA has assigned a PDUFA target action date of October 15, 2024 MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supple

      2/29/24 8:30:00 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.

      BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. ("Alfasigma") and Intercept Pharmaceuticals, Inc. ("Intercept") announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion of Alfasigma's successful tender offer to purchase all outstanding shares of common stock of Intercept for USD 19.00 per share, net to the seller thereof in cash, without interest, less any applicable withholding of taxes, Alfasigma acquired all remaining shares of common stock of Intercept through a merger pursuant to Section 251(h) of the General Corporation Law of the St

      11/8/23 9:13:49 AM ET
      $ICPT
      Biotechnology: Pharmaceutical Preparations
      Health Care